Related Experiment Video
Updated: Nov 1, 2025
Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation
Published on: July 23, 2012
Role of microRNAs As Biomarkers in Sepsis-Associated Encephalopathy
Rebeca Osca-Verdegal1,2, Jesús Beltrán-García2,3, Federico V Pallardó1,2,3
1Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Valencia, Spain.
Abstract:
Sepsis-associated encephalopathy (SAE) is a neurological complication of sepsis, characterized by brain dysfunction without any direct central nervous system infection. The diagnosis of SAE is currently a challenge. In fact, problems in making a diagnosis of SAE cause a great variability of incidence that can reach up to 70% of all septic patients. Even more, despite SAE is the most frequent type of encephalopathy occurring in critically ill patients, the molecular mechanisms that guide its progression have not been completely elucidated. On the other hand, miRNAs have proven to be excellent biomarkers for both diagnosis and prognosis, especially in brain pathologies because of their small size they can cross the blood-brain barrier easier than other biomolecules. The identification of new miRNAs as biomarkers may help to improve SAE diagnosis and prognosis and also to design new therapies for this clinical manifestation that produces diffuse cerebral dysfunction. This review is focused on SAE physiopathology and the need to have clear criteria for its diagnosis; thus, this work postulates some miRNA candidates to be used for SAE biomarkers because of their role in both, neurological damage and sepsis.
Insights
Sepsis-associated encephalopathy (SAE) diagnosis is challenging. This review explores miRNAs as potential biomarkers for improved diagnosis, prognosis, and therapy of this common critical illness complication.
Area of Science:
- Neuroscience
- Critical Care Medicine
- Molecular Biology
Background:
- Sepsis-associated encephalopathy (SAE) is a frequent neurological complication in sepsis patients, presenting diffuse brain dysfunction without direct central nervous system infection.
- Current diagnostic challenges lead to significant incidence variability (up to 70%), highlighting the need for improved diagnostic criteria and understanding of molecular mechanisms.
- SAE is the most common encephalopathy in critically ill patients, yet its underlying molecular pathways remain poorly understood.
Purpose of the Study:
- To review the pathophysiology of SAE and emphasize the critical need for clear diagnostic criteria.
- To identify and postulate microRNA (miRNA) candidates as potential biomarkers for SAE diagnosis and prognosis.
- To explore the potential of miRNAs in developing novel therapeutic strategies for SAE.
Main Methods:
- Literature review focusing on SAE pathophysiology and current diagnostic limitations.
- Analysis of existing research on the role of miRNAs in neurological disorders and sepsis.
- Identification of specific miRNAs implicated in both neurological damage and septic conditions.
Main Results:
- MicroRNAs (miRNAs) show promise as diagnostic and prognostic biomarkers due to their stability and ability to cross the blood-brain barrier.
- Specific miRNAs have been identified with roles in neurological damage and sepsis, suggesting their potential utility in SAE.
- The review highlights the potential for miRNAs to serve as valuable tools for improving SAE management.
Conclusions:
- Clear diagnostic criteria for SAE are urgently needed to reduce incidence variability and improve patient outcomes.
- MicroRNAs represent a promising avenue for developing reliable biomarkers to aid in the diagnosis and prognosis of SAE.
- Further research into miRNA biomarkers could lead to targeted therapies for SAE, addressing diffuse cerebral dysfunction in sepsis.
